Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4psrtz/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Gamida Cell - Piramal Enterprises - Aeolus - Cleveland BioLabs - Soligenix - NeoStem - Pluristem - Cumberland - Cellerant - Humanetics - Meabco - ActoKine - Priaxon - ProCertus BioPharm - Angion Biomedica - Onconova - Avaxia Biologics - Bolder Biotechnology - Stemedica Cell Technologies - Biothera - Terapio - Neumedicines - RxBio For more information visit http://www.researchandmarkets.com/research/4psrtz/radiation
CBLI: 0.28 (+0.01)
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 207.77 (+0.02), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), CBLI: 0.28 (+0.01)
Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Marketwired - Thu Nov 13, 9:22AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the current standard-of-care therapy, gemcitabine, against different models of pancreatic ductal adenocarcinoma (PDA), including models of gemcitabine-resistant tumors. The reported studies were conducted by scientists at Roswell Park, SUNY Downstate Medical Center and Buffalo Biolabs, LLC.
CBLI: 0.28 (+0.01)
Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 2:10PM CST
CBLI: 0.28 (+0.01)
Cleveland BioLabs EPS of $0.07
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:13AM CST
CBLI: 0.28 (+0.01)
Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Marketwired - Wed Nov 05, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2014.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
ACCESSWIRE - Tue Nov 04, 4:09PM CST
BUFFALO, NY / ACCESSWIRE / November 4, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Wednesday, November 5, 2014 at 10:00 AM Eastern Time.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Marketwired - Tue Oct 28, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended September 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 0.28 (+0.01)
HWCC, XOP, CBLI, RVBD, EXLS, CEP Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Oct 07, 5:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Houston Wire & Cable Co (NASDAQ:HWCC), Canadian Overseas Petroleum Ltd (NYSE:XOP), Cleveland BioLabs Inc (NASDAQ:CBLI), Riverbed Technology Inc (NASDAQ:RVBD), EXLSERVICE HOLDINGS, INC. (NASDAQ:EXLS), Constellation Energy Partners LLC (NYSE:CEP) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EXLS: 28.69 (+0.21), HWCC: 12.20 (-0.09), RVBD: 20.35 (+0.01), CEP: 3.35 (-0.06), XOP: 49.05 (-0.89), CBLI: 0.28 (+0.01)
Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612 in Russian Federation
Marketwire - Mon Sep 15, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced approval from the Ministry of Health of the Russian Federation to start a Phase 1 clinical trial with CBLB612, a drug in development for the induction and mobilization of hematopoietic stem cells (HSC).
CBLI: 0.28 (+0.01)
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.46 (unch), CGEN: 8.58 (-0.17), SPPI: 6.90 (+0.15), CBLI: 0.28 (+0.01)
Cleveland BioLabs and Sabby Announce Resolution of Litigation
Marketwire - Mon Sep 08, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively, "Sabby"
CBLI: 0.28 (+0.01)
CBLI, EDU, CLR, LL, CEVA, MSFG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 04, 9:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Cleveland BioLabs Inc (NASDAQ:CBLI), New Oriental Education & Technology Group Inc (NYSE:EDU), Continental Resources Inc (NYSE:CLR), Lumber Liquidators Holdings Inc (NYSE:LL), CEVA Inc (NASDAQ:CEVA), MainSource Financial Group Inc (NASDAQ:MSFG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLR: 38.78 (-1.48), CEVA: 18.37 (+0.56), EDU: 20.35 (-0.04), LL: 63.91 (-0.41), CBLI: 0.28 (+0.01), MSFG: 20.38 (-0.01)
Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Marketwire - Wed Sep 03, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3
Marketwire - Tue Sep 02, 3:30PM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on September 3, 2014, it will report the outcome of the Company's July meeting with the U.S. Food and Drug Administration (FDA), and will host a conference call at 11:00 a.m. ET.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Tue Sep 02, 8:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, September 8-10, in New York, NY.
CBLI: 0.28 (+0.01)
Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress
Marketwire - Thu Aug 07, 6:01AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2014.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
ACCESSWIRE - Wed Aug 06, 3:49PM CDT
BUFFALO, NY / ACCESSWIRE / August 6, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 10:00 AM Eastern Time.
CBLI: 0.28 (+0.01)
Cleveland BioLabs to Report Second Quarter 2014 Financial Results and Provide Operational Update on August 7
Marketwire - Tue Jul 29, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on August 7, 2014, it will report its financial results for the second quarter ended June 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 0.28 (+0.01)
Cleveland BioLabs Reduces Debt With $3.5 Million At-the-Market Private Placement of Unregistered Stock
Marketwire - Wed Jun 18, 8:25AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it entered into a securities purchase agreement (the "Purchase Agreement"
CBLI: 0.28 (+0.01)